Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Abdel‐Rahman, Omar; Elsayed, Zeinab

doi:10.1002/14651858.cd011313.pub4

Cited by 6 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a growing body of literature to suggest that radioembolization might be an effective treatment option for patients with liverlimited, unresectable disease, [190][191][192][193][194][195] though additional RCTs are needed to determine the relative risks and benefits of TARE with Y-90 microspheres in patients with unresectable HCC and long-term impact on liver function. 196 Delivery of 205 Gy or greater to the tumor may be associated with increased OS. 197 Although radioembolization with Y-90 microspheres, like TAE and TACE, involves some level of particle-induced vascular occlusion, it has been proposed that such occlusion is more likely to be microvascular than macrovascular, and that the resulting tumor necrosis is more likely to be induced by radiation rather than ischemia.…”

Section: Arterially Directed Therapiesmentioning

confidence: 99%

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

D’Angelica

Abbott

et al. 2021

Journal of the National Comprehensive Cancer Network

640

416

View full text Add to dashboard Cite

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.

show abstract

Section: Arterially Directed Therapiesmentioning

confidence: 99%

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson¹,

D’Angelica

Abbott

et al. 2021

Journal of the National Comprehensive Cancer Network

640

416

View full text Add to dashboard Cite

show abstract

“…3,4 Although hepatectomy, liver transplantation, and radiofrequency ablation have been used to treat HCC, the treatment results remain unsatisfying because of long-term recurrence and drug resistance. 5,6…”

Section: Introductionmentioning

confidence: 99%

CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle

Rong

Zhong

et al. 2021

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

In our studies, cyclin B1 ( CCNB1) mRNA and protein were overexpressed in hepatocellular carcinoma (HCC) tissues compared with non-HCC tissues. Moreover, CCNB1 was overexpressed in the serum of HCC patients. The expression of CCNB1 was associated with several crucial clinicopathologic characteristics, and the HCC patients with overexpressed CCNB1 had worse overall survival outcomes. In the screening of interactional genes, a total of 266 upregulated co-expression genes, which were positively associated with CCNB1, were selected from the datasets, and 67 downregulated co-expression genes, which were negatively associated with CCNB1, were identified. The key genes might be functionally enriched in DNA replication and the cell cycle pathways. CDC20, CCNA2, PLK1, and FTCD were selected for further research because they were highly connected in the protein-protein interaction networks. Upregulated CDC20, CCNA2, and PLK1 and downregulated FTCD might result in undesirable overall survival outcomes for HCC patients. The univariate Cox analysis results showed that CDC20 and PLK1 might be two independent risk factors, while FTCD might be protective in HCC. Therefore, CCNB1 may participate in the cell cycle of HCC by regulating DNA replication, and CCNB1 may provide a direction for the diagnosis of early-stage HCC and targeted HCC therapy.

show abstract

“…In the last 2 decades, numerous randomized controlled clinical trials targeted improving the OS of unresectable HCCs. ( 27 , 28 , 29 , 30 , 31 , 32 ) TACE is globally the most commonly used primary treatment modality in unresectable HCC. ( 33 , 34 ) Briefly, an unresectable HCC is traditionally first considered for TACE, which has wide availability, and treated with other options if TACE is not convenient.…”

Section: Discussionmentioning

confidence: 99%

Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders

et al. 2021

View full text Add to dashboard Cite

Optimal scoring system for clinical prognostic factors in patients with unresectable hepatocellular carcinoma (HCC) is currently uncertain. We aimed to develop and externally validate an easy to use tool, particularly for this population, and named it the "unresectable hepatocellular carcinoma prognostic index" (UHPI). We evaluated the data of patients with treatment-naive unresectable HCC who were diagnosed in the training center from 2010 to 2019 (n = 209). A simple prognostic model was developed by assigning points for each covariate in proportion to the beta coefficients in the Cox multivariable model. Predictive performance and distinction ability of the UHPI were further evaluated in an independent European validation cohort (n = 147) and compared with 11 other available models. A simple scoring system was derived, assigning 0.5/1/2 scores for six independent covariates including, the Child-Pugh score, Eastern Cooperative Oncology Group performance status, maximum tumor size, vascular invasion or extrahepatic metastasis, lymph node involvement, and alpha-fetoprotein. The UHPI score, ranging from 0 to 6, showed superior performance in prognosis prediction and outperformed 11 other staging or prognostic models, giving the highest homogeneity (c-index, 6-month and 1-year area under the receiver operator characteristic curves), lowest Akaike information criterion, and -2 log-likelihood ratio values. The UHPI score allocated well the risk of patients with unresectable HCC for mortality within the first year, using two cut-off values (low-risk, <0.5; intermediate-risk, 0.5-2; high-risk, >2). Conclusion: The UHPI score can predict prognosis better than other systems in subjects with unresectable HCC and can be used in clinical practice or trials to estimate the 6-month and 1-year survival probabilities for this group. (Hepatology Communications 2022;6:633-645).

show abstract

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma

Abstract: Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma (Review)

Cited by 6 publications

References 23 publications

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle

Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders

Contact Info

Product

Resources

About